Generics Ireland-headquartered Shire says that it has received a Paragraph IV Notice Letter from Zydus Pharmaceuticals USA, part of India's Zydus Cadila, advising of the filing of an Abbreviated New Drug Application for a generic version of Shire's 1.2g mesalamine delayed release tablets, Lialda, which is approved for the induction of remission in patients with active, mild to moderate ulcerative colitis. 1 June 2010